Overview
Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.
Current Appointments & Affiliations
James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
·
2023 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics
·
2012 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Chief, Division of Biostatistics
·
2019 - Present
Biostatistics & Bioinformatics,
Basic Science Departments
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trial.
Journal Article Clin Cancer Res · January 26, 2026 PURPOSE: Androgen receptor pathway inhibitors (ARPIs), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance, and most eventually ... Full text Link to item CiteDocetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal Article JAMA Netw Open · January 2, 2026 IMPORTANCE: Docetaxel has been a standard treatment for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Cabazitaxel, a related taxane, was approved in 2010 for patients with mCRPC who had been previously treated with docetaxel. The comp ... Full text Link to item CiteHow To Interpret Subgroup Analyses from Prospective Randomized Clinical Trials: What Clinicians Need To Know.
Journal Article Eur Urol · January 2026 Subgroup analyses must be approached with caution. Only prespecified, well-powered analyses with formal interaction testing and validation can support strong claims; exploratory findings require confirmation. Integration of statistical rigor with clinical ... Full text Link to item CiteRecent Grants
The COVID-19 and Cancer Consortium (CCC19) Registry
ResearchPrincipal Investigator · Awarded by Rhode Island Hospital · 2024 - 2029Assessing Prognoses and Validating Surrogate Endpoints for Clinical Outcomes in Metastatic Hormone Sensitive Prostate Cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2025 - 2028Research Triangle Center of Excellence in Regulatory Science and Innovation (CERSI)
ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028View All Grants
Education, Training & Certifications
University of Texas Health Sciences Center, Houston ·
1994
Ph.D.